Generic drug companies have been trying to navigate through the persistent problem of US drug pricing pressure, but the issue has yet to resolve. Second quarter financials at generic drug manufacturers like Teva Pharmaceutical Industries Ltd., Sandoz International GMBH, Mylan NV and others were weighed down by the US market, due to continued pricing pressure, slow uptake of new complex generics and other company-specific factors.
Price erosion, spurred by customer consolidation and the US FDA's faster ANDA approvals, has impacted generic drug revenues negatively for at least three years. Also see "Generic Manufacturers Try To Up Their Game As US Pressure Persists" - Scrip, 16 June, 2017
